TABLE 51

Glyphosate
104 Week Combined Chronic Feeding/Oncogenicity Study in Rats With 52 Week Interim Kill
Incidence of Histological Findings : Males and Females
Oncogenicity Study

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
ABDOMEN:			(1)				(1)			(2)	(2)
Vasculitis			0				0			0	1
Focal chronic inflammation			0				1			0	0
Fat necrosis			1				0			2	1
ACCESSORY SEX GLAND(S):								(1)		(1)	(1)
CLITORAL GLAND: cystic duct(s)								1		0	1
CLITORAL GLAND: abscess(es)								0		1	0
ADRENALS:		(49)	(25)	(17)	(21)	(49)	(48)	(26)	(29)	(30)	(49)
No abnormality detected		15	16	13	10	15	6	5	5	6	6
Unilateral focal cortical hyperplasia		0	0	0	2	0	0	2	1	1	1
Focal cortical hyperplasia		1	1	0	0	3	1	0	0	0	0
Unilateral CORTICAL CARCINOMA [M]		0	0	0	0	1	0	0	0	1	0
Metastasising CORTICAL CARCINOMA [M]		0	0	0	0	0	0	0	0	1	0
Unilateral CORTICAL ADENOMA [B]		2	0	0	0	0	0	0	0	0	0
Unilateral focal medullary hyperplasia		5	0	0	1	7	3	1	1	0	1
Bilateral focal medullary hyperplasia		1	0	0	1	3	1	0	1	0	0
Focal medullary hyperplasia		0	0	0	0	0	1	0	0	0	0
Unilateral PHAEOCHROMOCYTOMA [M]		1	0	0	0	1	0	0	0	0	0
Unilateral PHAEOCHROMOCYTOMA [B]		7	1	1	1	8	5	0	0	1	0*

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
ADRENALS:		(49)	(25)	(17)	(21)	(49)	(48)	(26)	(29)	(30)	(49)
Bilateral PHAEOCHROMOCYTOMA [B]		1	0	0	0	1	1	0	0	0	0
Infiltration by histiocytic cells		0	0	0	0	1	0	0	0	0	0
Haemorrhagic degeneration		6	1	1	2	1	35	18	21	18	32
Only one examined		1	1	0	1	0	0	1	0	0	0
Accessory cortical nodule		1	0	0	0	0	0	0	0	0	0
Infiltration by lymphoma cells		0	0	0	2	0	1	0	0	0	0
Medulla not examined		0	0	0	0	0	0	0	1	0	1
Only one medulla examined		0	0	0	0	0	3	0	1	1	1
Subcapsular hyperplasia		1	0	0	0	0	0	0	0	0	0
Diffuse cortical hyperplasia		0	0	0	0	1	0	0	0	0	0
Cortical small-cell focus(i)		1	0	0	0	0	0	0	0	0	0
Zona glomerulosa not examined histologically		0	0	0	0	0	1	0	0	0	0
Focal cortical cell vacuolation		8	3	1	1	2	2	1	0	0	1
Diffuse cortical cell vacuolation		0	0	0	0	1	0	0	1	0	0
Necrosis		1	0	0	1	0	2	0	2	0	0
Focal cortical cell hypertrophy		18	3	4	3	15	18	5	8	13	23
Grade(++++) focal cortical cell hypertrophy		0	0	0	0	0	0	1	0	0	1
Increased haemopoiesis		0	0	0	0	0	2	0	0	0	1
Haemopoiesis		0	0	0	0	1	0	0	2	4	0
Unilateral atrophy		0	0	0	0	0	1	0	0	1	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
ADRENALS:	(49)	(25)	(17)	(21)	(49)	(48)	(26)	(29)	(30)	(49)
Angiectasis	0	0	0	1	0	0	0	0	0	0
Autolysed, diagnosis difficult	5	7	3	3	1	2	1	2	2	3
Extra section(s) examined	0	0	0	0	1	0	0	0	0	0
AORTA:	(50)	(25)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
No abnormality detected	50	25	18	20	50	50	28	29	30	50
Medial mineralisation	0	0	1	1	0	0	0	0	0	0
Autolysed, diagnosis difficult	0	0	1	0	0	0	0	0	0	0
BRAIN:	(50)	(25)	(19)	(21)	(50)	(49)	(28)	(29)	(30)	(50)
No abnormality detected	38	18	15	16	42	34	14	20	16	33
GRANULAR CELL TUMOUR [M]	0	0	0	0	1	0	0	0	0	0
Meningeal infiltration by histiocytic cells	0	0	0	0	1	0	0	0	0	0
Compression by pituitary	10	5	3	4	5	9	12	9	12	11
Infiltration by lymphoma cells	0	0	0	1	0	0	0	0	0	0
Focal chronic meningitis	0	0	1	0	0	0	0	0	0	0
Focal gliosis	0	0	0	0	0	0	0	0	0	2
GLIOMA [M]	2	1	0	0	1	0	1	0	0	0
Autolysed, diagnosis difficult	1	0	1	0	0	0	0	0	0	2

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
BRAIN:	(50)	(25)	(19)	(21)	(50)	(49)	(28)	(29)	(30)	(50)
Infiltration by pituitary tumour	1	1	0	1	0	6	4	1	2	6
Forebrain not available for histological examination	0	0	0	0	5	3	0	0	0	0
Cerebellum not examined histologically	0	0	0	0	0	1	0	0	0	1
CAECUM:	(42)	(8)	(6)	(12)	(43)	(43)	(23)	(23)	(26)	(42)
No abnormality detected	42	8	6	12	43	41	23	23	26	42
Infiltration by histiocytic cells	0	0	0	0	0	1	0	0	0	0
Infiltration by lymphoma cells	0	0	0	0	0	1	0	0	0	0
Autolysed, diagnosis difficult	0	0	0	1	0	1	0	1	1	1
CERVIX:						(1)				
No abnormality detected						1				
COLON:	(43)	(11)	(7)	(13)	(44)	(46)	(25)	(26)	(27)	(44)
No abnormality detected	43	11	6	13	42	46	25	26	27	44
Infiltration by histiocytic cells	0	0	0	0	1	0	0	0	0	0
Perivasculitis	0	0	0	0	1	0	0	0	0	0
Hypertrophy in muscle layer	0	0	1	0	0	0	0	0	0	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
COLON:	(43)	(11)	(7)	(13)	(44)	(46)	(25)	(26)	(27)	(44)
Dilatation	0	0	1	0	1	0	0	0	0	0
Autolysed, diagnosis difficult	1	1	1	1	1	2	0	2	0	2
DUODENUM:	(47)	(12)	(10)	(14)	(46)	(47)	(26)	(27)	(29)	(46)
No abnormality detected	46	12	10	14	45	46	26	27	29	45
CARCINOMA [M]	0	0	0	0	0	0	0	0	0	1
Infiltration by histiocytic cells	0	0	0	0	0	1	0	0	0	0
Serosal perivasculitis	1	0	0	0	0	0	0	0	0	0
Autolysed, diagnosis difficult	4	2	3	2	2	3	0	1	0	3
EYES:	(3)			(1)	(2)		(1)	(1)		
No abnormality detected	1			0	2		0	0		
Panophthalmitis	1			0	0		1	0		
Keratitis	1			0	0		0	0		
Haemorrhage	0			1	0		0	1		
Autolysed, diagnosis difficult	1			0	0		0	0		
HEART:	(50)	(24)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(49)
No abnormality detected	12	7	5	6	13	32	20	21	21	31

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
HEART:		(50)	(24)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(49)
Infiltration by histiocytic cells		0	0	0	0	0	1	1	0	0	1
Infiltration by leukaemic cells		0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells		0	0	0	0	0	0	1	0	0	0
Cardiomyopathy(mineralised)		1	1	0	1	0	0	0	0	0	0
Cardiomyopathy											
	(Grade +/-)	3	5	1	1	6	5	5	5	4	4
	(Grade +)	18	8	7	10	21	8	2	2	4	12
	(Grade ++)	15	3	5	3	7	0	0	0	0	0
	(Grade +++)	1	0	0	0	0	0	0	0	0	0
Total incidence for score expanded finding		37	16	13	14	34	13	7	7	8	16
Metastasis from primary in adrenal		0	0	0	0	0	0	0	0	1	0
Atrial thrombus		0	1	1	0	0	0	0	0	0	0
Myocarditis		0	0	1	0	3	3	1	2	1	1
Vascular mineralisation		0	0	1	0	0	0	0	0	0	0
Focus(i) of mast-cell infiltration		0	0	0	0	0	1	0	0	0	0
Endocarditis		0	0	0	0	1	1	0	0	0	0
Autolysed, diagnosis difficult		0	0	0	0	0	1	0	0	0	0
ILEUM:		(42)	(8)	(7)	(12)	(43)	(45)	(23)	(25)	(25)	(42)
No abnormality detected		42	8	7	12	43	44	23	25	25	42

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
ILEUM:		(42)	(8)	(7)	(12)	(43)	(45)	(23)	(25)	(25)	(42)
Infiltration by lymphoma cells		0	0	0	0	0	1	0	0	0	0
Autolysed, diagnosis difficult		0	0	1	0	0	0	0	1	1	1
JEJUNUM:		(43)	(9)	(8)	(15)	(45)	(45)	(24)	(26)	(28)	(44)
No abnormality detected		42	9	8	15	45	45	24	26	28	44
Mucosa damaged		1	0	0	0	0	0	0	0	0	0
Autolysed, diagnosis difficult		0	0	1	3	1	1	0	1	1	1
KIDNEYS:		(50)	(50)	(50)	(50)	(50)	(50)	(49)	(50)	(49)	(50)
No abnormality detected		7	12	10	6	8	9	12	17	10	13
Mesenchymal TUMOUR [M]		0	0	0	0	0	1	0	0	0	0
Unilateral TUBULAR ADENOMA [B]		1	0	0	0	0	0	0	0	0	0
Metastasising urothelial CARCINOMA [M]		0	0	0	1	0	0	0	0	0	0
Infiltration by histiocytic cells		0	0	0	0	2	1	1	0	1	1
Abnormal shape		0	0	0	1	0	0	0	0	0	0
Urothelial hyperplasia											
(Grade +/-)		1	1	0	0	0	2	3	3	0	1
(Grade +)		1	1	2	2	3	14	11	9	9	0***
(Grade ++)		1	0	0	0	0	2	3	1	0	0
Total incidence for score expanded finding		3	2	2	2	3	18	17	13	9	1***

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
KIDNEYS:		(50)	(50)	(50)	(50)	(50)	(50)	(49)	(50)	(49)	(50)
Nephropathy											
	(Grade +/-)	5	8	5	9	15*	14	7	5*	6	13
	(Grade +)	20	17	16	20	10*	9	12	10	19*	7
	(Grade ++)	9	8	12	7	9	2	2	0	1	6
	(Grade +++)	6	4	0*	1	0*	0	0	0	0	1
Total incidence for score expanded finding		40	37	33	37	34	25	21	15	26	27
Infiltration by lymphoma cells		0	0	0	2	0	0	0	0	0	0
Basophilic tubules		1	0	1	1	4	1	1	0	0	0
Tubular dilatation		2	1	1	3	0	2	4	10*	3	4
Pelvic dilatation		1	0	1	3	1	0	0	1	1	1
Papillary necrosis		1	0	0	1	1	0	0	0	0	0
Cortical tubular hyaline inclusions		0	1	0	0	2	1	1	0	0	1
Mineral deposit(s)		0	0	2	0	0	0	0	0	0	0
Cortical brown pigment deposit(s)		0	0	0	1	1	1	0	3	2	0
Lymphocytic infiltration		1	0	0	0	1	1	1	0	0	0
Cortical tubular vacuolation		0	0	0	0	0	1	0	1	0	0
Pyelonephritis		0	0	1	1	0	0	0	0	0	0
Pyelitis		0	0	0	2	2	0	2	1	1	0
Perivasculitis		0	0	0	0	0	0	0	0	0	1
Glomerular nephropathy		0	0	1	0	0	0	0	0	0	0
Tubular necrosis		0	0	0	0	0	2	1	0	1	1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
KIDNEYS:	(50)	(50)	(50)	(50)	(50)	(50)	(49)	(50)	(49)	(50)
Inflammatory cell infiltrate	0	0	1	0	0	0	0	0	0	1
Focal inflammation	0	0	1	0	0	1	1	0	0	0
Cyst(s)	2	0	1	2	1	1	1	0	2	0
Autolysed, diagnosis difficult	7	14	9	4	7	7	3	5	4	6
Tumour infiltration	0	0	0	0	0	0	1	0	0	0
LACRIMAL GLANDS:	(1)				(1)					
No abnormality detected	1				0					
Focal cellular atypia	0				1					
LIVER:	(50)	(50)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
No abnormality detected	2	2	6	6	1	8	2	5	5	7
Haemangioma present	0	0	1	0	0	0	0	1	0	0
Focal hepatocellular hyperplasia	0	0	1	0	0	0	0	0	1	0
HEPATOCELLULAR CARCINOMA MULTIPLE [M]	0	1	0	0	0	0	0	0	0	0
HEPATOCELLULAR CARCINOMA [M]	0	0	1	0	0	0	0	0	0	0
HEPATOCELLULAR ADENOMA MULTIPLE [B]	0	0	0	1	0	0	1	3	0	0
HEPATOCELLULAR ADENOMA [B]	2	1	1	1	2	0	0	0	1	2
Infiltration by histiocytic cells	0	0	0	1	1	1	1	0	2	2

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
LIVER:		(50)	(50)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Foamy hepatocytes (bifurcation of median lobe)		0	1	0	0	0	0	0	0	0	0
Foamy hepatocytes		8	1*	5	7	4	5	9	6	11	6
Portal tract sclerosis											
	(Grade +/-)	5	1	1	2	1	1	1	3	5	5
	(Grade +)	8	22**	11	19*	13	2	3	2	3	3
	(Grade ++)	5	2	4	2	2	1	0	0	0	0
Total incidence for score expanded finding		18	25	16	23	16	4	4	5	8	8
Spongiosis hepatis		17	18	22	17	11	0	1	1	1	0
Clear cell focus(i)											
	(Grade +/-)	1	0	1	1	1	0	1	0	0	0
	(Grade +)	8	4	7	5	7	4	3	0	5	3
	(Grade ++)	1	3	1	4	5	2	0	0	0	0
	(Grade +++)	0	0	0	0	1	0	0	0	0	0
Total incidence for score expanded finding		10	7	9	10	14	6	4	0*	5	3
Pale cell focus(i)											
	(Grade +/-)	1	0	0	2	0	0	1	1	1	0
	(Grade +)	9	8	9	3	8	5	5	6	7	3
	(Grade ++)	2	6	6	1	2	1	2	0	0	1
	(Grade +++)	0	0	0	0	2	0	0	0	0	1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
LIVER:	(50)	(50)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Total incidence for score expanded finding	12	14	15	6	12	6	8	7	8	5
Basophilic focus(i)										
(Grade +/-)	1	2	1	0	0	1	0	0	3	1
(Grade +)	9	2	5	2	5	11	6	10	15	11
(Grade ++)	0	0	2	0	3	7	8	14	5	2
(Grade +++)	0	0	0	0	0	3	1	2	1	0
Total incidence for score expanded finding	10	4	8	2*	8	22	15	26	24	14
Infiltration by leukaemic cells	0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells	0	0	0	1	0	1	1	0	0	2
Dilated sinusoids	1	1	0	0	0	0	0	0	0	0
Bile duct hyperplasia										
(Grade +/-)	4	1	0	1	1	0	3	1	0	3
(Grade +)	15	13	15	19	11	4	8	8	5	3
(Grade ++)	8	9	5	2	3	2	2	0	2	5
Total incidence for score expanded finding	27	23	20	22	15*	6	13	9	7	11
Extramedullary haemopoiesis	1	0	0	0	1	4	2	0	1	5
Lymphocytic infiltration	1	0	0	0	1	0	0	0	0	0
Haemocyst(s)	0	0	0	0	0	0	1	0	0	0
Vacuolation	18	13	11	12	15	13	16	18	16	13

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
LIVER:		(50)	(50)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Necrosis		0	2	2	1	0	3	4	0	4	5
Inflammatory cell infiltrate		2	3	2	3	5	2	6	3	2	2
Chronic periportal inflammation		0	0	0	0	1	0	0	0	0	0
Focal inflammation		1	0	4	5	4	1	0	0	1	2
Periportal hypertrophy		0	0	0	0	0	1	1	0	0	0
Centrilobular hypertrophy		0	0	1	0	0	0	1	0	0	0
Subcapsular fibrosis		3	0	0	0	0	0	0	0	0	0
Diffuse degeneration		0	1	1	0	0	0	0	0	0	0
Bile duct cyst(s)		0	0	1	1	0	2	0	2	2	2
Cyst(s)		0	0	0	0	0	1	0	0	0	0
Congestion		5	0	0	0	3	1	0	0	0	0
Angiectasis		16	8	13	12	13	15	22	10	12	13
Autolysed, diagnosis difficult		5	6	9	3	3	7	3	2	4	5
Increased mitotic rate		0	0	1	0	1	0	1	0	0	0
Extra section(s) examined		0	0	0	0	0	0	0	0	1	2
Tumour infiltration		0	0	0	0	0	0	1	0	0	0
LUNGS:		(50)	(49)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
No abnormality detected		20	29	20	27	25	25	36*	34	35	24
Metastasising SQUAMOUS-CELL CARCINOMA MULTIPLE [M]		0	0	0	1	0	0	0	0	0	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
LUNGS:	(50)	(49)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Metastasising ALVEOLAR/BRONCHIOLAR CARCINOMA MULTIPLE [M]	0	0	0	0	0	0	0	1	0	0
ALVEOLAR/BRONCHIOLAR ADENOMA [B]	2	0	1	2	0	0	0	0	0	0
SARCOMA [M]	0	0	0	0	0	1	0	0	0	0
Infiltration by histiocytic cells	0	0	0	1	2	0	1	0	2	2
Infiltration by leukaemic cells	0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells	0	0	0	1	0	0	1	0	0	1
Interstitial pneumonitis	2	4	4	2	3	3	1	2	1	3
Increased alveolar macrophages	9	7	5	1*	6	3	2	2	1	3
Food present	1	0	0	0	0	0	0	0	0	0
Focal alveolitis	13	9	16	13	8	16	9	12	9	12
Metastasis from primary in uterus	0	0	0	0	0	0	1	0	0	0
Metastasis from primary in thyroid	0	0	0	1	0	0	0	0	0	0
Metastasis from primary in kidney	0	0	0	1	0	0	0	0	0	0
Metastasis from primary in adrenal	0	0	0	0	0	0	0	0	1	0
Alveolar pigmented macrophages	0	1	1	0	0	0	0	0	0	0
Perivascular lymphocytic infiltration	2	1	0	0	0	0	0	0	0	0
Grade(++++) granuloma(ta)	0	0	0	0	0	0	0	0	0	1
Granuloma(ta)	0	3	0	2	1	0	0	0	0	0
Focal chronic pleurisy	0	0	1	0	0	0	0	0	0	0
Oedema	1	0	3	0	1	0	0	0	0	0
Inflammatory cell infiltrate	0	0	1	1	0	2	0	0	1	2

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
LUNGS:		(50)	(49)	(49)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Haemorrhage(s)		0	0	1	0	0	0	1	0	0	0
Alveolar epithelialisation		0	1	0	0	0	1	0	0	0	1
Congestion		4	3	3	1	5	0	0	0	0	1
Bronchopneumonia		1	0	0	0	0	0	0	0	0	0
Autolysed, diagnosis difficult		3	8	3	4	1	4	2	4	2	4
Tumour metastasis (primary site unknown)		0	0	1	0	0	0	1	0	0	0
Only two lobes available for histological examination		0	0	0	0	0	0	0	0	0	1
Only one lobe examined		0	0	0	0	0	0	1	0	0	0
LYMPH NODE(S):		(10)	(6)	(5)	(5)	(15)	(23)	(9)	(15)	(21)	(28)
Infiltration by histiocytic cells		0	1	0	0	0	0	1	1	0	0
Infiltration by leukaemic cells		0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells		0	0	0	1	0	1	1	0	0	1
Lymph nodes local to mass or with necropsy findings with no abnormality detected		5	3	3	3	9	15	3	10	16	16
Lymph nodes local to mass or with necropsy findings but were not available for histological examination		1	1	0	1	2	1	1	2	2	3
Tumour metastasis		0	0	0	1	0	0	0	0	1	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
LYMPH NODE(S):		(10)	(6)	(5)	(5)	(15)	(23)	(9)	(15)	(21)	(28)
Pigmented macrophages		0	0	0	0	0	2	0	0	0	2
Reactive		3	1	2	0	3	9	3	4	4	11
Cyst(s)		1	0	0	0	1	1	0	0	0	1
Congestion		0	1	0	0	1	0	1	1	2	1
Autolysed, diagnosis difficult		0	0	0	0	1	0	0	0	0	0
LYMPHORETICULAR/HAEMOPOIETIC TISSUE:		(1)	(2)		(3)	(5)	(4)	(2)	(1)	(2)	(5)
HISTIOCYTIC SARCOMA [M]		1	1		1	3	3	1	1	2	3
LYMPHOMA in thymus only [M]		0	1		0	1	0	0	0	0	0
LYMPHOMA [M]		0	0		2	1	1	1	0	0	2
MAMMARY GLANDS:		(45)	(25)	(17)	(21)	(47)	(50)	(28)	(29)	(30)	(50)
No abnormality detected		16	11	7	11	22	3	2	5	1	2
FIBROADENOMA MULTIPLE [B]		0	0	0	0	0	10	6	5	8	12
FIBROADENOMA [B]		0	0	0	0	1	19	6	12	11	17
CARCINOMA MULTIPLE [M]		0	0	0	0	0	1	0	0	0	2
Metastasising CARCINOMA [M]		0	0	0	0	0	0	0	0	1	0
CARCINOMA [M]		0	1	0	0	0	6	1	1	2	4
ADENOMA [B]		0	0	0	0	0	2	1	3	4	3
Focal alveolar hyperplasia		0	0	0	0	0	0	2	1	4	1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
MAMMARY GLANDS:	(45)	(25)	(17)	(21)	(47)	(50)	(28)	(29)	(30)	(50)
Infiltration by histiocytic cells	0	0	0	0	0	0	1	0	0	1
Mammary development	28	14	10	10	24	40	24	16	28	38
Focus(i) of pigmented macrophages	0	0	0	0	0	0	0	1	0	0
Focal lymphocytic infiltration	1	0	0	0	0	0	0	0	0	0
Chronic inflammation	0	0	0	0	0	1	0	2	0	0
Inflammation	0	0	0	0	0	2	0	0	0	0
Abscess(es)	0	0	0	0	0	0	0	0	0	1
Autolysed, diagnosis difficult	0	1	0	0	0	1	0	0	1	1
MESENTERIC LYMPH NODE:	(50)	(24)	(19)	(21)	(50)	(48)	(28)	(29)	(30)	(49)
No abnormality detected	47	23	19	19	44	46	28	26	30	45
Haemangioma present	1	1	0	0	0	0	0	0	0	0
Infiltration by histiocytic cells	1	0	0	0	2	0	0	1	0	0
Infiltration by leukaemic cells	0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells	0	0	0	0	0	1	0	0	0	1
Lymphoid depletion	0	0	0	1	0	0	0	0	0	0
Pigmented macrophages	0	0	0	0	0	1	0	1	0	2
Reactive	0	0	0	0	1	0	0	1	0	1
Cyst(s)	1	0	0	0	0	0	0	0	0	0
Congestion	0	0	0	1	2	1	0	1	0	0
Autolysed, diagnosis difficult	1	0	0	0	1	0	0	0	0	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
MESENTERY:					(1)						(1)
MESOTHELIOMA [B]					0						1
Abscess(es)					1						0
OESOPHAGUS:		(49)	(24)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
No abnormality detected		49	24	19	20	50	50	28	29	30	49
Infiltration by histiocytic cells		0	0	0	0	0	0	0	0	0	1
Infiltration by thyroid tumour		0	0	0	1	0	0	0	0	0	0
OPTIC NERVE:		(1)		(1)	(1)						
No abnormality detected		1		1	1						
Autolysed, diagnosis difficult		0		1	0						
OVARIES:							(50)	(28)	(29)	(29)	(50)
No abnormality detected							19	13	9	9	20
Unilateral GRANULOSA/THECAL CELL TUMOUR [B]							0	0	1	0	0
Infiltration by histiocytic cells							1	0	0	1	0
Only one examined							1	0	0	0	0
Cystic follicle(s)							10	4	7	4	10

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
OVARIES:							(50)	(28)	(29)	(29)	(50)
Stromal hyperplasia							1	2	1	2	4
Bursal cyst(s)							2	0	1	2	1
Atrophy							21	12	12	15	19
Autolysed, diagnosis difficult							4	1	1	0	3
Tumour infiltration							0	1	0	0	0
PANCREAS:		(50)	(24)	(17)	(21)	(49)	(49)	(27)	(29)	(29)	(49)
No abnormality detected		21	13	13	16	37**	41	21	24	26	42
Islet hyperplasia		2	0	0	0	1	0	0	0	0	0
EXOCRINE CARCINOMA [M]		0	0	0	0	0	1	0	0	0	0
EXOCRINE ADENOMA [B]		3	0	1	0	0	0	0	0	0	0
ISLET ADENOMA [B]		7	1	2	2	1	1	2	2	2	1
Infiltration by histiocytic cells		0	0	0	0	1	1	0	1	0	0
Dilated duct(s)		1	0	0	0	0	0	1	0	0	0
Acinar atrophy		9	7	1	3	6	4	3	1	1	4
Pigment deposit(s)		0	0	0	0	0	0	0	1	0	0
Lymphocytic infiltration		0	0	0	0	1	0	0	0	0	0
Granuloma(ta)		1	0	0	0	0	0	0	0	0	0
Thrombus (canalised)		0	0	0	0	1	0	0	0	0	0
Perivasculitis		1	0	0	0	1	1	0	0	0	2
Interstitial oedema		0	1	0	0	0	0	0	0	0	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
PANCREAS:	(50)	(24)	(17)	(21)	(49)	(49)	(27)	(29)	(29)	(49)
Perivascular inflammatory cell infiltrate	0	1	0	0	0	0	0	0	0	0
Acinar hypertrophy	3	1	0	0	1	0	0	0	0	0
Ductal hyperplasia	4	1	0	0	1	0	0	0	0	0
Autolysed, diagnosis difficult	3	9	5	5	3	1	1	2	0	4
Extra section(s) examined	0	0	0	0	0	0	0	1	0	0
Infiltration by uterus tumour	0	0	0	0	0	0	1	0	0	0
PARATHYROIDS:	(44)	(20)	(17)	(19)	(46)	(46)	(26)	(23)	(24)	(41)
No abnormality detected	42	20	17	18	46	45	26	23	23	38
Unilateral focal hyperplasia	1	0	0	0	0	0	0	0	0	0
Unilateral ADENOMA [B]	1	0	0	0	0	1	0	0	0	1
Only one examined	14	5	6	1	15	9	4	6	5	15
Fibrosis	0	0	0	0	0	0	0	0	0	2
Haemorrhagic cyst(s)	0	0	0	1	0	0	0	0	0	0
Cyst(s)	0	0	0	0	0	0	0	0	1	0
Autolysed, diagnosis difficult	0	0	0	0	0	0	0	0	0	1
PITUITARY:	(50)	(24)	(19)	(21)	(50)	(49)	(28)	(29)	(30)	(49)
No abnormality detected	15	10	8	9	24	7	3	9	2	6
Only anterior lobe examined	5	5	1	0	6	0	0	1	0	3

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
PITUITARY:	(50)	(24)	(19)	(21)	(50)	(49)	(28)	(29)	(30)	(49)
CARCINOMA [M]	1	1	0	1	0	7	5	1	2	7
ADENOMA MULTIPLE [B]	0	0	0	0	0	2	0	0	0	4
ADENOMA [B]	28	12	8	7	17*	33	19	19	25	30
Focal hyperplasia	4	1	2	3	7	0	0	0	0	2
Intermediate lobe hyperplasia	1	0	0	0	0	0	0	0	0	0
Damaged	0	0	0	0	1	0	0	0	0	0
Posterior lobe not examined histologically	3	0	4	1	2	1	0	0	0	2
Cyst(s)	4	0	2	1	5	1	1	0	2	3
Autolysed, diagnosis difficult	1	1	4	2	3	2	1	2	1	1
Anatomical defect (possibly congenital)	0	0	0	0	1	0	0	0	0	0
PROSTATE:	(50)	(24)	(18)	(21)	(50)					
No abnormality detected	42	23	14	17	43					
CARCINOMA [M]	0	0	0	0	1					
ADENOMA [B]	0	0	0	0	1					
Focal lymphocytic infiltration	1	0	0	0	0					
Inflammation	6	1	4	4	5					
Interstitial fibrosis	1	0	0	0	0					
Autolysed, diagnosis difficult	0	0	2	0	0					

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
RECTUM:		(43)	(12)	(8)	(13)	(44)	(46)	(26)	(28)	(27)	(43)
No abnormality detected		42	12	8	13	43	45	25	28	27	43
Infiltration by histiocytic cells		0	0	0	0	1	0	1	0	0	0
Infiltration by lymphoma cells		0	0	0	0	0	1	0	0	0	0
Lymphocytic hyperplasia		1	0	0	0	0	0	0	0	0	0
Dilatation		0	0	0	0	1	0	0	0	0	0
Autolysed, diagnosis difficult		1	2	2	1	1	3	1	4	0	1
SALIVARY GLAND:		(50)	(46)	(49)	(50)	(49)	(50)	(50)	(50)	(50)	(48)
No abnormality detected		1	1	0	0	0	1	1	1	0	0
PAROTID: NAD		35	30	25	8***	12***	35	33	31	21**	8***
SUBLINGUAL: NAD		48	45	49	50	47	49	47	49	46	45
MANDIBULAR: NAD		41	40	27**	8***	17***	38	40	37	32	21**
PAROTID: not examined histologically		0	1	3	1	0	9	7	5	7	1*
SUBLINGUAL: not examined histologically		1	0	0	0	2	0	2	0	4	2
MANDIBULAR: not examined histologically		0	0	0	0	0	0	1	0	0	0
PAROTID: FIBROMA [B]		1	0	0	0	0	0	0	0	0	0
MANDIBULAR: FIBROMA [B]		0	0	0	0	0	0	0	1	0	0
PAROTID: infiltration by histiocytic cells		0	1	0	0	0	0	0	0	0	1
MANDIBULAR: infiltration by histiocytic cells		0	0	0	0	1	0	0	0	0	1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
SALIVARY GLAND:		(50)	(46)	(49)	(50)	(49)	(50)	(50)	(50)	(50)	(48)
PAROTID: dilated/cystic duct(s)		0	1	0	0	0	0	0	0	1	0
MANDIBULAR: hyperplastic focus(i)		0	0	0	0	1	0	0	0	0	0
PAROTID: lymphocytic infiltration		1	0	0	0	1	0	0	0	0	0
MANDIBULAR: perivasculitis		0	0	0	0	1	0	0	0	0	0
MANDIBULAR: inflammation		0	0	0	0	0	1	0	0	0	1
SUBLINGUAL: acinar hypertrophy		0	0	0	0	0	0	0	0	0	1
PAROTID: ductal hyperplasia		0	0	0	0	1	1	0	0	0	1
MANDIBULAR: ductal hyperplasia		0	0	0	0	0	0	0	0	0	1
MANDIBULAR: hyperplasia		1	0	0	0	0	0	0	0	0	0
PAROTID: acinar atrophy		5	4	0	0	2	1	1	1	0	3
PAROTID: cellular alteration											
	(Grade +/-)	4	4	8	3	4	1	2	2	2	5
	(Grade +)	3	5	9	21***	14**	0	5	9**	9**	13***
	(Grade ++)	0	0	4	17***	18***	1	1	1	9*	18***
	(Grade +++)	0	0	0	0	0	0	0	0	1	2
Total incidence for score expanded finding		7	9	21**	41***	36***	2	8	12**	21***	38***
MANDIBULAR: cellular alteration											
	(Grade +/-)	7	5	10	14	9	2	0	3	1	6
	(Grade +)	0	0	12***	28***	22***	9	8	9	15	19*
	(Grade ++)	0	0	0	0	0	0	0	0	2	1
Total incidence for score expanded finding		7	5	22***	42***	31***	11	8	12	18	26**

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
SALIVARY GLAND:	(50)	(46)	(49)	(50)	(49)	(50)	(50)	(50)	(50)	(48)
Autolysed, diagnosis difficult	7	10	10	9	6	7	3	4	5	5
SCIATIC NERVE:	(50)	(25)	(19)	(21)	(50)	(49)	(28)	(29)	(30)	(49)
No abnormality detected	44	25	16	19	46	49	27	28	30	49
Infiltration by histiocytic cells	0	0	0	0	0	0	1	0	0	0
Chronic inflammatory cell infiltrate	0	0	0	0	1	0	0	0	0	0
Axonal degeneration	6	0	3	2	3	0	0	1	0	0
Autolysed, diagnosis difficult	0	0	2	0	0	0	0	0	0	0
SEMINAL VESICLES:	(2)	(2)	(2)	(2)	(2)					
No abnormality detected	1	2	2	1	2					
Serosal inflammation	1	0	0	0	0					
Haemorrhage(s)	0	0	0	1	0					
SKELETAL MUSCLE:	(50)	(25)	(19)	(21)	(50)	(50)	(27)	(29)	(30)	(50)
No abnormality detected	45	25	18	20	45	50	26	29	29	50
Infiltration by histiocytic cells	0	0	0	0	0	0	1	0	0	0
Focal lymphocytic infiltration	1	0	0	0	0	0	0	0	0	0
Myositis	0	0	0	1	2	0	0	0	1	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
SKELETAL MUSCLE:		(50)	(25)	(19)	(21)	(50)	(50)	(27)	(29)	(30)	(50)
Focal inflammatory cell infiltrate		0	0	0	0	1	0	0	0	0	0
Myofibre degeneration		4	0	1	0	2	0	0	0	0	0
Autolysed, diagnosis difficult		0	0	1	0	0	0	0	0	0	0
SKIN/SUBCUTIS:		(50)	(25)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
No abnormality detected		31	15	11	12	29	42	23	20	25	43
TRICHOEPITHELIOMA [M]		0	1	0	0	1	0	0	0	0	0
BASAL CELL TUMOUR [M]		1	0	0	0	0	0	0	1	0	0
SEBACEOUS CARCINOMA [M]		0	0	0	0	0	1	0	0	0	0
ZYMBAL'S GLAND: CARCINOMA [M]		1	0	0	0	0	1	0	1	0	0
SQUAMOUS-CELL CARCINOMA [M]		0	0	0	0	1	0	1	0	0	0
SARCOMA [M]		0	1	1	0	0	1	0	0	0	0
SCHWANNOMA [M]		0	1	0	0	0	0	0	0	0	0
PAPILLOMA [B]		0	0	0	1	0	0	0	0	0	0
FIBROSARCOMA [M]		1	1	0	2	2	0	0	0	0	0
FIBROMA MULTIPLE [B]		1	0	1	0	1	0	0	0	0	0
FIBROMA [B]		7	2	0	1	5	1	2	2	1	2
Dermal FIBROMA MULTIPLE [B]		0	1	0	0	0	0	0	0	0	0
Dermal FIBROMA [B]		2	0	2	1	2	0	0	0	0	0
LIPOMA [B]		1	0	1	0	0	0	0	0	0	2

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
SKIN/SUBCUTIS:	(50)	(25)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
INTRACUTANEOUS CORNIFYING EPITHELIOMA MULTIPLE [B]	0	0	0	0	1	0	0	0	0	0
INTRACUTANEOUS CORNIFYING EPITHELIOMA [B]	1	2	0	0	4	1	0	0	0	0
Infiltration by histiocytic cells	0	0	0	1	0	0	0	0	0	1
Subcutaneous oedema	0	1	0	0	0	0	0	0	0	0
Epithelial hyperplasia	1	0	0	0	0	0	0	1	0	0
Dermal fibrosis	0	1	0	0	0	0	0	0	0	0
Inflammation	1	0	2	1	3	0	0	1	2	0
Sebaceous cyst(s)	0	0	0	0	1	0	0	0	0	0
Dermal cyst(s)	0	1	0	0	5	1	0	1	1	0
Abscess(es)	0	0	1	0	2	0	0	1	1	0
Autolysed, diagnosis difficult	0	1	0	0	0	0	0	0	0	0
Pododermatitis	4	3	2	2	4	4	4	1	1	3
SPINAL CORD:	(50)	(25)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
No abnormality detected	49	25	19	19	46	50	27	29	29	50
Infiltration by lymphoma cells	0	0	0	2	0	0	0	0	0	0
Haemorrhage(s)	0	0	0	1	0	0	0	0	0	0
Neuronal degeneration	1	0	0	0	4	0	1	0	1	0
Autolysed, diagnosis difficult	0	0	1	0	0	0	0	0	0	0
Cervical not examined	1	0	0	0	0	0	0	0	0	1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
SPINAL CORD:		(50)	(25)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
Lumbar not examined		1	1	4	0	3	0	0	2	6	4
SPLEEN:		(50)	(25)	(19)	(21)	(49)	(49)	(27)	(29)	(30)	(50)
No abnormality detected		35	16	8	9	33	12	11	5	9	18
Haemangiosarcoma present		0	0	0	0	1	0	0	0	0	0
Infiltration by histiocytic cells		0	0	0	1	1	1	0	1	1	0
Infiltration by leukaemic cells		0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells		0	0	0	2	0	1	1	0	0	1
Lymphoid depletion		0	0	0	0	0	1	0	0	0	1
Increased extramedullary haemopoiesis		11	7	8	9	8	26	9	13	15	21
Inflammatory cell infiltrate		0	0	0	1	0	0	0	0	0	0
Chronic serosal inflammation		1	0	0	0	0	0	0	0	0	0
Lymphoid hyperplasia		1	0	0	2	1	0	0	0	1	0
Small cyst(s)		0	0	0	0	1	0	0	0	0	0
Congestion		2	0	0	0	0	0	0	0	0	0
Increased brown pigment		1	3	3	0	4	10	7	10	6	11
Autolysed, diagnosis difficult		4	11	6	2	3	4	1	2	1	3
Infiltration by uterus tumour		0	0	0	0	0	0	1	0	0	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
STERNUM:		(50)	(25)	(19)	(21)	(50)	(50)	(28)	(29)	(30)	(50)
No abnormality detected		50	25	19	19	49	48	26	29	29	50
Infiltration by histiocytic cells		0	0	0	1	1	0	1	0	1	0
Infiltration by lymphoma cells		0	0	0	1	0	0	1	0	0	0
Bone marrow hyperplasia		0	0	0	0	0	2	0	0	0	0
Autolysed, diagnosis difficult		1	0	0	0	0	0	0	0	0	0
STOMACH:		(50)	(23)	(15)	(18)	(50)	(48)	(27)	(27)	(29)	(47)
No abnormality detected		19	17	11	13	29	33	14	20	15	23
Dilated/cystic gland(s)		23	5	3	1	17	11	10	2	14	20
Keratinised cyst(s)		0	0	0	0	0	0	0	1	0	0
Ulceration in glandular region		0	0	0	0	0	0	0	1	0	0
Ulceration in non-glandular region		3	0	1	1	1	1	2	1	0	0
Perivasculitis		0	0	0	0	2	0	0	0	0	0
Submucosal oedema in non-glandular region		2	0	0	1	0	1	1	1	0	0
Mineralisation		0	0	1	1	0	0	0	0	0	0
Inflammation		6	1	1	1	3	1	2	1	1	5
Focal hyperplasia in non-glandular region		1	0	0	0	0	0	0	0	0	0
Hyperplasia in non-glandular region		3	1	1	3	3	3	5	2	0	3
Autolysed, diagnosis difficult		8	12	8	5	6	4	1	1	2	3

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
SUBMANDIBULAR LYMPH NODE:	(6)	(3)	(2)	(2)	(3)	(6)	(1)	(4)	(1)	(12)
No abnormality detected	0	2	1	0	1	2	0	1	0	3
Infiltration by histiocytic cells	0	0	0	0	1	0	0	1	0	0
Infiltration by lymphoma cells	0	0	0	0	0	1	0	0	0	0
Reactive	6	0	1	1	0*	3	1	2	1	7
Congestion	0	1	0	2	1	0	0	0	0	2
TESTES:	(50)	(25)	(19)	(21)	(50)					
No abnormality detected	37	21	16	18	35					
Unilateral focal interstitial cell hyperplasia	0	0	0	1	0					
Bilateral focal interstitial cell hyperplasia	0	0	0	1	2					
Unilateral INTERSTITIAL-CELL ADENOMA [B]	3	1	0	0	0					
Bilateral INTERSTITIAL-CELL ADENOMA [B]	0	0	0	0	1					
INTERSTITIAL-CELL ADENOMA [B]	0	0	0	0	1					
Infiltration by histiocytic cells	0	0	0	0	1					
Only one examined	0	1	0	0	0					
Tubular atrophy	9	3	3	1	10					
Sperm granuloma	1	0	1	0	0					
Granuloma(ta)	1	0	0	0	0					
Perivasculitis	2	0	0	0	1					

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
TESTES:		(50)	(25)	(19)	(21)	(50)					
Mineralisation		0	1	0	1	1					
Autolysed, diagnosis difficult		1	1	1	0	1					
THORAX:						(1)					
MESOTHELIOMA [M]						1					
THYMUS:		(48)	(23)	(19)	(18)	(44)	(48)	(27)	(26)	(28)	(46)
No abnormality detected		40	21	19	16	37	35	20	19	17	26
THYMOMA [B]		1	0	0	0	0	0	0	0	0	0
Infiltration by histiocytic cells		0	0	0	1	2	0	0	0	1	0
Infiltration by leukaemic cells		0	0	0	0	1	0	0	0	0	0
Infiltration by lymphoma cells		0	1	0	1	1	0	0	0	0	1
Focal lymphoid hyperplasia		0	0	0	0	1	0	0	0	0	0
Epithelial hyperplasia		2	0	0	0	0	3	0	0	0	3
Haemorrhage(s)		0	0	0	0	0	0	0	0	2	0
Perivascular fibrosis		1	0	0	0	0	0	0	0	0	0
Cyst(s)		5	1	0	0	1	12	7	7	7	18
Congestion		2	0	0	0	1	0	0	0	0	0
Autolysed, diagnosis difficult		2	0	0	0	1	3	1	1	1	1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
THYROIDS:		(50)	(21)	(17)	(21)	(49)	(50)	(27)	(29)	(29)	(49)
No abnormality detected		35	19	15	16	33	34	21	18	22	31
Unilateral FOLLICULAR CARCINOMA [M]		0	0	0	1	0	0	0	0	0	0
Unilateral FOLLICULAR ADENOMA [B]		0	0	0	1	2	0	0	0	0	0
Unilateral focal follicular-cell hyperplasia		0	0	0	0	0	0	0	0	0	1
Unilateral C-CELL CARCINOMA [M]		0	0	0	0	1	0	0	0	0	0
Bilateral metastasising C-CELL CARCINOMA [M]		0	0	0	1	0	0	0	0	0	0
Unilateral C-CELL ADENOMA MULTIPLE [B]		0	0	0	0	0	0	0	0	1	1
Unilateral C-CELL ADENOMA [B]		9	1	1	2	7	6	1	1	1	6
Bilateral C-CELL ADENOMA [B]		0	0	0	0	1	2	0	0	0	0
Unilateral ADENOMA [B]		0	0	0	0	1	0	0	0	0	0
Unilateral focal c-cell hyperplasia		2	1	0	0	4	9	4	1	0	5
Bilateral focal c-cell hyperplasia		1	0	0	0	2	1	1	0	1	0
Dilated/cystic follicle(s)		2	0	0	0	2	1	0	3	4	6
Only one examined		0	0	0	1	0	0	0	0	0	0
Diffuse c-cell hyperplasia		1	0	1	0	0	2	0	6	1	5
Lymphocytic infiltration		1	0	0	0	0	0	0	0	0	0
Perivasculitis		0	0	0	0	1	0	0	0	0	0
Bilateral diffuse follicular-cell hyperplasia		0	0	0	0	0	0	0	1	0	0
Autolysed, diagnosis difficult		7	10	7	8	5	5	1	5	0	5

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
THYROIDS:	(50)	(21)	(17)	(21)	(49)	(50)	(27)	(29)	(29)	(49)
Extra section(s) examined	0	0	0	2	1	1	0	0	0	0
TONGUE:							(1)			
Epithelial hyperplasia							1			
TRACHEA:	(50)	(23)	(18)	(21)	(50)	(50)	(27)	(29)	(30)	(49)
No abnormality detected	49	23	18	20	50	50	27	29	30	49
Inflammatory cell infiltrate	1	0	0	0	0	0	0	0	0	0
Autolysed, diagnosis difficult	1	0	0	0	0	2	0	1	0	1
Infiltration by thyroid tumour	0	0	0	1	0	0	0	0	0	0
URETER:				(1)						
Infiltration by lymphoma cells				1						
URINARY BLADDER:	(49)	(25)	(19)	(20)	(49)	(50)	(28)	(29)	(30)	(49)
No abnormality detected	47	23	15	15	45	50	27	29	30	49
Urothelial hyperplasia (Grade +)	0	0	0	0	1	0	0	0	0	0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS / TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
	MALES					FEMALES				
	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
URINARY BLADDER:	(49)	(25)	(19)	(20)	(49)	(50)	(28)	(29)	(30)	(49)
Urothelial hyperplasia (Grade ++)	0	0	0	2	0	0	0	0	0	0
Total incidence for score expanded finding	0	0	0	2	1	0	0	0	0	0
Infiltration by lymphoma cells	0	0	0	1	0	0	0	0	0	0
Eosinophilic contents	0	2	0	1	3	0	0	0	0	0
Perivasculitis	0	0	0	0	1	0	0	0	0	0
Inflammation	2	0	1	3	0	0	0	0	0	0
Haemorrhage(s)	1	0	0	1	0	0	0	0	0	0
Dilatation	0	0	3	0	0	0	0	0	0	0
Autolysed, diagnosis difficult	0	8	2	1	0	4	1	0	0	2
Infiltration by uterus tumour	0	0	0	0	0	0	1	0	0	0
UTERUS:						(49)	(28)	(29)	(30)	(49)
No abnormality detected						38	26	19	20	39
STROMAL SARCOMA [M]						0	0	0	1	0
Metastasising endometrial CARCINOMA [M]						0	1	0	0	0
Endometrial CARCINOMA [M]						0	0	0	2	0
Endometrial ADENOMA [B]						1	0	0	0	0
POLYP MULTIPLE [B]						1	0	0	0	0
POLYP [B]						2	1	1	1	3

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 51 (continued)

FINDINGS	TREATMENT	INCIDENCE OF LESIONS (NUMERIC)									
		MALES					FEMALES				
		Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day	Grp 1 0 mg/kg /day	Grp 2 10 mg/kg /day	Grp 3 100 mg/kg /day	Grp 4 300 mg/kg /day	Grp 5 1000 mg/kg /day
UTERUS:							(49)	(28)	(29)	(30)	(49)
Infiltration by histiocytic cells							1	0	0	1	0
Dilated/cystic gland(s)							6	0	8	4	4
Pyometra							0	0	1	0	0
Myometrial hypertrophy							0	0	0	0	1
Dilatation							1	0	2	3	3
Autolysed, diagnosis difficult							3	0	0	1	1
VAGINA:									(1)		
No abnormality detected									1		
VASCULAR SYSTEM:		(1)	(1)	(1)		(1)			(1)		
HAEMANGIOMA [B]		1	1	1		0			1		
HAEMANGIOSARCOMA [M]		0	0	0		1			0		

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52

Glyphosate
104 Week Combined Chronic Feeding/Oncogenicity Study in Rats with 52 Week Interim Kill
Incidence of Histological Findings up to Week 52: Males and Females
Toxicity Study

FINDINGS / TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
LIVER:	(15)	(15)	(15)	(15)	(15)			(2)		(1)
No abnormality detected	2	3	1	6	3			1		0
Basophilic focus(i)										
(Grade +/-)	0	2	2	3	0			0		0
Total incidence for score expanded finding	0	2	2	3	0			0		0
Pale cell focus(i)										
(Grade +/-)	1	4	1	0	3			0		0
(Grade +++)	0	0	1	0	0			0		0
Total incidence for score expanded finding	1	4	2	0	3			0		0
Clear cell focus(i)										
(Grade +/-)	3	1	2	1	1			0		0
(Grade +)	0	0	1	1	0			0		0
Total incidence for score expanded finding	3	1	3	2	1			0		0
Periportal hepatocyte hypertrophy	0	0	0	0	0			1		0
Spongiosis hepatis	0	0	0	1	0			0		0
Focus(i) of angiectasis	1	0	0	0	0			0		0
Focal cellular change with vascular changes	1	0	0	0	0			0		0
Foamy hepatocytes (bifurcation of median lobe)	3	0	0	2	0			0		0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
LIVER:	(15)	(15)	(15)	(15)	(15)			(2)		(1)
Bile duct hyperplasia	4	1	3	2	4			0		0
Vacuolation	3	6	3	1	3			0		0
Increased Kupffer-cell pigmentation	0	0	1	0	0			0		0
Necrosis	0	0	1	1	0			1		0
Inflammatory change(s)	8	5	7	4	7			0		1
Congestion	0	0	0	0	0			0		1
HEART:	(15)				(15)			(2)		(1)
No abnormality detected	3				7			1		1
Cardiomyopathy	12				8			1		0
KIDNEYS:	(15)	(15)	(15)	(15)	(15)			(1)		(1)
No abnormality detected	2	1	9*	5	6			0		1
Nephropathy										
(Grade +/-)	10	4	1**	3*	4			0		0
(Grade +)	2	3	0	1	1			0		0
(Grade ++)	0	0	1	0	0			1		0
Total incidence for score expanded finding	12	7	2***	4**	5*			1		0
Basophilic tubules										
(Grade +/-)	1	3	4	4	2			0		0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
KIDNEYS:	(15)	(15)	(15)	(15)	(15)			(1)		(1)
Total incidence for score expanded finding	1	3	4	4	2			0		0
Tubular dilatation (Grade +/-)	0	1	0	0	1			0		0
Total incidence for score expanded finding	0	1	0	0	1			0		0
Urothelial hyperplasia	1	1	1	0	2			0		0
Mineral deposit(s)	0	0	0	0	1			0		0
Pyelitis	3	5	0	2	1			0		0
Focus(i) of inflammation	0	1	0	0	0			0		0
Cyst(s)	0	0	0	1	2			0		0
LUNGS:	(15)	(15)	(15)	(15)	(15)			(2)		(1)
No abnormality detected	8	9	8	4	6			1		1
Alveolitis	2	1	1	4	0			0		0
Area(s) of interstitial pneumonitis	2	0	3	1	4			1		0
Focus(i) of increased alveolar macrophages	3	6	5	5	3			0		0
Focal inflammation	0	0	0	0	2			0		0
Lymphoid tissue increase	1	0	0	2	2			1		0
Medial hypertrophy	0	0	2	1	2			0		0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
LUNGS:	(15)	(15)	(15)	(15)	(15)			(2)		(1)
Focal mineral deposit(s)	1	0	1	2	0			0		0
Agonal congestion	0	0	0	0	0			1		0
SPLEEN:	(15)				(15)			(2)		(1)
No abnormality detected	15				15			2		1
ADRENALS:	(15)				(15)			(2)		(1)
No abnormality detected	8				6			2		1
Unilateral medullary hyperplasia	0				2			0		0
Unilateral cellular change (cortex)	3				3			0		0
Unilateral cellular change with degeneration/vascular dilatation	1				0			0		0
Subcapsular pale cell focus(i)	2				5			0		0
Focal subcapsular cellular change	1				0			0		0
THYMUS:	(15)				(13)			(1)		(1)
No abnormality detected	13				11			0		0
THYMOMA(TA) [B]	0				0			1		0
Increased atrophy	2				2			0		1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
TESTES:		(15)				(15)			(2)		(1)
No abnormality detected		12				12			2		1
Interstitial-cell ADENOMA [B]		0				1			0		0
Tubular atrophy		3				2			0		0
PROSTATE:		(15)				(15)			(2)		(1)
No abnormality detected		15				13			1		1
Inflammation		0				2			1		0
SEMINAL VESICLES:											(1)
Secretion decreased											1
BRAIN:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
Fore-brain not available for examination		7				8			0		0
SPINAL CORD:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
SKELETAL MUSCLE:	(15)				(15)			(2)		(1)
No abnormality detected	15				15			2		1
PANCREAS:	(15)				(15)			(2)		(1)
No abnormality detected	10				13			1		1
Acinar atrophy	3				0			1		0
Focal inflammation	2				1			0		0
Pigment deposit(s)	0				1			0		0
SALIVARY GLAND:	(15)	(15)	(15)	(15)	(15)			(2)		(1)
MANDIBULAR: NAD	15	15	14	10*	3***			2		0
MANDIBULAR: cellular alteration (Grade +)	0	0	1	5*	12***			0		1
Total incidence for score expanded finding	0	0	1	5*	12***			0		1
PAROTID: NAD	14	15	6**	3***	0***			1		1
PAROTID: cellular alteration (Grade +)	0	0	8**	8**	4			1		0
(Grade ++)	0	0	1	4	7**			0		0
(Grade +++)	0	0	0	0	4			0		0
Total incidence for score expanded finding	0	0	9***	12***	15***			1		0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
SALIVARY GLAND:	(15)	(15)	(15)	(15)	(15)			(2)		(1)
PAROTID: inflammation	0	0	0	1	0			0		0
PAROTID: not examined histologically	1	0	0	0	0			0		0
SUBLINGUAL: NAD	15	15	15	13	15			2		1
SUBLINGUAL: not examined histologically	0	0	0	2	0			0		0
SUBMANDIBULAR LYMPH NODE:	(1)									
Plasmacytosis	1									
PITUITARY:	(15)				(15)			(1)		(1)
No abnormality detected	14				13			1		0
GLIOMA [M]	0				0			0		1
Hyperplasia	1				2			0		0
SKIN/SUBCUTIS:	(15)				(15)			(2)		(1)
No abnormality detected	14				15			2		1
Area of ulceration with chronic, active inflammation	1				0			0		0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
MAMMARY GLANDS:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
URINARY BLADDER:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
AORTA:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
MESENTERIC LYMPH NODE:		(15)				(15)			(2)		(1)
No abnormality detected		15				14			1		1
Increased macrophage aggregation		0				0			1		0
Contains lymphosarcoma		0				1			0		0
THYROIDS:		(15)				(15)					(1)
No abnormality detected		9				11					1
FOLLICULAR ADENOMA [B]		1				0					0
C-CELL ADENOMA [B]		2				1					0
Diffuse c-cell hyperplasia		1				2					0

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
THYROIDS:		(15)				(15)					(1)
Dilated/cystic follicle(s)		2				1					0
PARATHYROIDS:		(14)				(14)			(2)		(1)
No abnormality detected		13				14			2		1
Pale cell focus(i)		1				0			0		0
TRACHEA:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
OESOPHAGUS:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
STOMACH:		(15)				(15)			(2)		(1)
No abnormality detected		8				11			2		0
Dilated/cystic gland(s)		7				4			0		0
Ulceration with inflammation/necrosis		0				0			0		1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
DUODENUM:		(15)				(15)			(1)		(1)
No abnormality detected		15				15			1		1
JEJUNUM:		(15)				(15)					(1)
No abnormality detected		15				15					1
ILEUM:		(15)				(15)					(1)
No abnormality detected		15				15					1
CAECUM:		(15)				(15)					(1)
No abnormality detected		15				15					1
COLON:		(15)				(15)					(1)
No abnormality detected		15				15					1
RECTUM:		(15)				(15)			(1)		(1)
No abnormality detected		15				15			1		1

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	MALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
SCIATIC NERVE:		(15)				(15)			(2)		(1)
No abnormality detected		15				15			2		1
STERNUM:		(15)				(15)			(2)		(1)
No abnormality detected		14				14			0		1
Fat vacuolation absent		0				1			0		0
Bone marrow reactive		0				0			1		0
Localised depressed haemopoiesis		1				0			0		0
Contains histiocytic sarcoma		0				0			1		0
LYMPHORETICULAR/HAEMOPOIETIC TISSUE:						(1)			(1)		
Metastasising HISTIOCYTIC SARCOMA(TA) [M]						0			1		
LYMPHOSARCOMA [M]						1			0		

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
LIVER:	(15)	(15)	(15)	(15)	(15)				(2)	
No abnormality detected	1	1	2	1	3				1	
HEPATOCELLULAR ADENOMA [B]	1	0	0	0	0				0	
Basophilic focus(i)										
(Grade +/-)	6	7	7	6	7				0	
(Grade +)	4	1	3	3	2				0	
(Grade ++)	2	2	0	2	0				0	
(Grade +++)	1	1	1	0	0				0	
Total incidence for score expanded finding	13	11	11	11	9				0	
Pale cell focus(i)										
(Grade +/-)	3	1	2	4	1				0	
Total incidence for score expanded finding	3	1	2	4	1				0	
Clear cell focus(i)										
(Grade +/-)	1	0	0	2	1				0	
Total incidence for score expanded finding	1	0	0	2	1				0	
Focal hepatocellular hypertrophy	1	1	0	0	0				0	
Periportal hepatocyte hypertrophy	0	0	0	1	0				0	
Spongiosis hepatis	0	0	1	1	0				0	
Subcapsular dilated sinusoids	0	2	0	0	0				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
LIVER:	(15)	(15)	(15)	(15)	(15)				(2)	
Foamy hepatocytes (bifurcation of median lobe)	3	3	4	2	1				0	
Increased Kupffer-cell pigmentation	1	0	0	0	0				0	
Necrosis	2	0	2	0	0				1	
Inflammatory change(s)	5	2	3	5	6				0	
Hepatocytes contain red blood cells (a few)	2	0	0	0	0				0	
Diffuse mitotic increase	0	1	0	0	0				0	
Increased multinucleate giant-cell(s)	0	0	0	0	1				0	
Focal fibrosis	0	1	0	0	0				0	
HEART:	(15)				(15)				(1)	
No abnormality detected	6				10				0	
Cardiomyopathy	9				5				1	
KIDNEYS:	(15)	(15)	(15)	(15)	(15)				(1)	
No abnormality detected	3	4	5	6	8				1	
Nephropathy										
(Grade +/-)	5	5	5	4	4				0	
(Grade +)	1	1	0	1	2				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
KIDNEYS:		(15)	(15)	(15)	(15)	(15)				(1)	
Nephropathy (Grade ++)		0	0	0	0	1				0	
Total incidence for score expanded finding		6	6	5	5	7				0	
Basophilic tubules (Grade +/-)		0	0	1	2	0				0	
Total incidence for score expanded finding		0	0	1	2	0				0	
Tubular dilatation (Grade +/-)		0	1	1	0	0				0	
Total incidence for score expanded finding		0	1	1	0	0				0	
Urothelial hyperplasia		8	5	5	2	0**				0	
Unilateral pelvic dilatation		1	0	0	0	0				0	
Mineral deposit(s)		4	4	2	1	0				0	
Increased tubular pigment deposit(s)		1	0	0	0	2				0	
Cyst(s)		1	0	0	0	0				0	
LUNGS:		(15)	(15)	(15)	(15)	(15)				(1)	
No abnormality detected		8	9	8	7	11				1	
Alveolitis		2	0	1	1	0				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
LUNGS:	(15)	(15)	(15)	(15)	(15)				(1)	
Area(s) of interstitial pneumonitis	2	4	1	1	3				0	
Focus(i) of increased alveolar macrophages	4	1	5	7	1				0	
Focal inflammation	0	1	0	1	0				0	
Focal epithelialisation	0	1	0	0	0				0	
Lymphoid tissue increase	0	0	1	0	0				0	
Medial hypertrophy	0	0	0	1	1				0	
Focal mineral deposit(s)	0	0	1	0	0				0	
SPLEEN:	(15)				(15)				(1)	
No abnormality detected	15				13				0	
Increased haemosiderin	0				2				0	
Increased extramedullary haemopoiesis	0				0				1	
ADRENALS:	(15)				(15)				(1)	
No abnormality detected	5				4				1	
PHAEOCHROMOCYTOMA [B]	1				0				0	
Cortical CARCINOMA [M]	1				0				0	
Unilateral cellular change (cortex)	1				2				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
ADRENALS:	(15)				(15)				(1)	
Unilateral cellular change with degeneration/vascular dilatation	0				2				0	
Subcapsular pale cell focus(i)	0				1				0	
Haemorrhagic degeneration	8				9				0	
THYMUS:	(15)				(15)				(1)	
No abnormality detected	8				12				1	
Epithelial hyperplasia	1				0				0	
Cystic duct(s)	5				2				0	
Increased atrophy	1				1				0	
OVARIES:	(15)				(15)				(1)	
No abnormality detected	4				4				0	
Absence of recent corpus luteum	11				11				0	
Interstitial tissue increased	0				1				0	
Follicular cyst(s)	10				7				1	
Cyst(s)	1				1				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
UTERUS:	(15)				(15)				(2)	
No abnormality detected	8				9				2	
Dilated/cystic gland(s)	4				5				0	
Dilatation in both horns	1				0				0	
Focal squamous metaplasia	0				1				0	
Glandular epithelial hyperplasia	1				0				0	
Focal endometrial hyperplasia	0				1				0	
Glandular abscess(es)	1				0				0	
BRAIN:	(15)				(15)				(2)	
No abnormality detected	15				14				2	
Compression by pituitary	0				1				0	
Fore-brain not available for examination	10				0***				0	
SPINAL CORD:	(15)				(15)				(2)	
No abnormality detected	15				15				2	
SKELETAL MUSCLE:	(15)				(15)				(2)	
No abnormality detected	15				15				2	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS / TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
	SURVIVORS					DECEDENTS				
	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
PANCREAS:	(15)				(15)				(1)	
No abnormality detected	15				13				1	
Acinar atrophy	0				2				0	
SALIVARY GLAND:	(15)	(15)	(15)	(15)	(15)				(1)	
MANDIBULAR: NAD	15	15	15	15	8**				1	
MANDIBULAR: cellular alteration (Grade +)	0	0	0	0	7**				0	
Total incidence for score expanded finding	0	0	0	0	7**				0	
PAROTID: NAD	15	14	13	7**	1***				1	
PAROTID: cellular alteration (Grade +)	0	0	2	5*	8**				0	
(Grade ++)	0	0	0	3	5*				0	
(Grade +++)	0	0	0	0	1				0	
Total incidence for score expanded finding	0	0	2	8**	14***				0	
PAROTID: not examined histologically	0	1	0	0	0				0	
SUBLINGUAL: NAD	15	13	13	13	15				1	
SUBLINGUAL: not examined histologically	0	2	2	2	0				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
SUBMANDIBULAR LYMPH NODE:										(1)	
Reactive										1	
PITUITARY:		(15)				(14)				(2)	
No abnormality detected		10				10				2	
Anterior lobe ADENOMA [B]		3				2				0	
Hyperplasia		2				2				0	
Focal mineral deposit(s)		0				1				0	
Intermediate lobe cyst(s)		0				1				0	
SKIN/SUBCUTIS:		(15)				(15)				(2)	
No abnormality detected		15				15				1	
Large abscess(es)		0				0				1	
MAMMARY GLANDS:		(15)				(15)				(2)	
No abnormality detected		6				12				2	
Intraductal CARCINOMA [M]		1				0				0	
Focal hyperplasia		1				0				0	
Dilated/cystic duct(s)		4				3				0	
Secretion present		8				3				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
MAMMARY GLANDS:		(15)				(15)				(2)	
Alveolar development		1				0				0	
URINARY BLADDER:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
AORTA:		(15)				(15)				(2)	
No abnormality detected		15				15				2	
MESENTERIC LYMPH NODE:		(15)				(15)				(2)	
No abnormality detected		14				15				2	
Congestion		1				0				0	
THYROIDS:		(15)				(15)				(1)	
No abnormality detected		11				10				1	
C-CELL ADENOMA [B]		1				0				0	
Unilateral focal c-cell hyperplasia		1				0				0	
Diffuse c-cell hyperplasia		2				4				0	
Dilated/cystic follicle(s)		1				2				0	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
PARATHYROIDS:		(14)				(12)				(2)	
No abnormality detected		14				12				2	
TRACHEA:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
OESOPHAGUS:		(15)				(15)				(2)	
No abnormality detected		15				15				2	
STOMACH:		(15)				(15)				(1)	
No abnormality detected		9				11				1	
Dilated/cystic gland(s)		6				4				0	
DUODENUM:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
JEJUNUM:		(15)				(15)				(1)	
No abnormality detected		15				15				1	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001

TABLE 52 (continued)

FINDINGS	TREATMENT	FEMALES : INCIDENCE OF LESIONS (NUMERIC)									
		SURVIVORS					DECEDENTS				
		Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day	Grp 1 0mg kg/day	Grp 2 10mg kg/day	Grp 3 100mg kg/day	Grp 4 300mg kg/day	Grp 5 1000mg kg/day
ILEUM:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
CAECUM:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
COLON:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
RECTUM:		(15)				(15)				(1)	
No abnormality detected		15				15				1	
SCIATIC NERVE:		(15)				(15)				(2)	
No abnormality detected		15				15				2	
STERNUM:		(15)				(15)				(2)	
No abnormality detected		15				15				2	

Figures in brackets represent the number of animals from which this tissue was examined histologically.
Significance of differences in a pairwise (Fisher's) test between control and each treatment group: * P<0.05, ** P<0.01, *** P<0.001